Sign in to view content

Twelve Month Safety and Efficacy Outcomes from a Phase 2 Study of APL-2 in Patients with Geographic Atrophy

David S. Boyer, MD

Video
Published 2017

Related

Efficacy, Durability, and Safety of Faricimab in DME: 2-Year Results From the Phase 3 YOSEMITE and RHINE Trials
Jennifer I. Lim, MD, FARVO, FASRS
Updates from the Field
2022
Results from Part 1 of the Phase 2/3 SIGLEC Trial Assessing AVD-104 for Geographic Atrophy: Glyco-immunologic Modulation of Macrophage Activity
Rishi P. Singh, MD
Updates from the Field
2024
Baseline Characteristics in the Phase 2 GOLDEN Study of IONIS-FB-LRx, an Investigational Antisense Oligonucleotide Designed to Treat AMD-Associated Geographic Atrophy
Glenn J. Jaffe, MD
Annual Meeting Talks
2022

Category: AMD-Neovascular

See more